Request for Proposal (RFP) for Biomedical and Biotechnical innovations in Climate Change and Human Health - Supplier Q&A

#	Question	Answer
1.	BudgetWe would like to ask if Wellcome could share their budget expectations for the delivery of the project.Do you have an indicative budget in mind for this effort?	Wellcome will be guided by the supplier as to what is a reasonable budget for this activity, as we do not want to limit ambition or innovation. Proposals are in part assessed on value for money and as such we would expect to see a detailed budget breakdown (for example on time and resources) to allow Wellcome to feedback as needed with the awarded supplier.
2.	Given Wellcome's extensive networks in the area of global health, will it be possible to make use of these networks if it is appropriate for the needs of the project	Yes, we can put you in touch with researchers and institutes that you would like to speak to.
3.	Our expectation is that this RFP is focussed on research in the area of interest, not public health or hospital based interventions, is this correct?	That is correct.
4.	Survey with the research community - if one is carried out, will you require ethical approval?	We have a data gating questionnaire that the selected provider will be asked to fill out. We will also provide wording to be included in the surveys to inform the participants about what information will be collected and how their answers will be used.
5.	Given the project's timeline (May to July 2024), could you clarify the flexibility regarding project delivery dates?	We are happy to be flexible and will discuss the deliverables timeline when a provider is chosen, please feel free to include your suggested timeline in your proposal.
6.	How does the project timeline fit into the overall timeline for the development of Wellcome's strategy to build its portfolio in this domain?	We are in the initial phase of considering how and if to fund in this domain so this project will be one of the first steps.

#	Question	Answer
7.	Does Wellcome hope that the findings of this report will inform the mechanisms they use to allocate funds to researchers operating in the domain?	You are welcome to make suggestions about the best methods to fund in this domain, but it is not within the expectations of this report.
8.	We understand the need for a strong qualitative interpretation of findings and synthesis of recommendations for new areas to explore. Could Wellcome suggest potential partners or networks within the biomed/biotech space to facilitate this aspect of the project?	We can share some initial thoughts, but we would predominantly like to learn from the provider who the potential partners and networks are.
9.	Does Wellcome have connections to funders operating in Asia? If so, will Wellcome be able to make connections with these groups and individuals to facilitate the research?	We can initiate introductions with funders in this space, both in Asia and more globally.
10.	Are there any specific methodologies or approaches that Wellcome prefers for this type of research?	Similar projects have involved workshops, desk-based research, surveys and interviews. However, ultimately it is up to the provider how they think they will best achieve the objectives.
11.	Countries within Asia	
	Could you provide more details on the expectations for the initial global review section versus the deeper dive into the Asian context? Are there any particular countries of interest within Asia?	The level of detail that the provider can go into on both the global review and the in-depth review of the Asian landscape will highly depend on the findings as the review develops. If there is a large amount of work being carried out in Aisa, then we would expect more time spent on this aspect of the report. However, if the provider finds that there is not a large amount of work or stakeholders engaged in Asia then they will be able to spend more time and resources investigating the wider global landscape. We do not want to stipulate which countries in Asia to focus on, as this will also be based on the findings as the investigation progresses.

#	Question	Answer
12.	Wellcome engagement	
	How much time from Wellcome staff will be allocated to liaise with the successful party, beyond monthly check in meetings? In addition to the monthly check points, will there be a Wellcome contact or team who will engage more regularly?	The provider will have 2 main contacts from the Climate and Impacts Adaptation team at Wellcome, they will be available for a maximum of 4 hours each per week.
13.	Final Report	
	 Would the final, externally facing report be published by Wellcome or the successful party? Which party will be responsible for the design and communications effort around the report?? For the external-facing report, who is the intended audience and do you have any preferences on format? What is the anticipated balance of focus in the report between what research exists and is needed, who is conducting / could conduct it and who is funding / could fund it? 	The report should be published on Wellcome Open Research but may also be published where the chosen provider suggests. The chosen provider will be responsible for the report, the design and the communication of the report but we can share guidance in the form of a 'Wellcome Style Guide' which details formatting and tone of voice that we prefer. Wellcome also holds the right to also communicate it. The intended audience is Wellcome, however the report will be openly published as it may be beneficial for other funders, researchers or research organisations who may be interested in or may already be funding in this space.
	What is the anticipated balance of focus in the report between biomedical knowledge generation versus biotechnology research and development?	The balance of focus will depend on the findings of the review as it develops.
	One of the core questions to be addressed in the report is on "research questions or topics that Wellcome could pursue to have the greatest short-term impact" – could you please define "short-term" in years?	However initial thoughts to give a very rough estimate would be 40% on what research exists and is needed, 40% on who is doing the research and who has the infrastructure/ capacity; and 20% on who is already funding in this space and who is motivated to.
		The balance of focus between biomedical knowledge generation versus biotechnology research and development will be determined by the findings of the review.
		We will reiterate that this will be based on what the provider finds and would likely evolve during the project.

#	Question	Answer
		As a guide we say short-term impact is $\sim 3 - 5$ years.